Abstract

Abstract:
Objective: Fabry disease (FD) is an X-linked lysosomal storage disease (LSD), that occurs due to deficient activity of the enzyme alpha-galactosidase A (a-GalA) with multisystemic involvement. The disease can present with a wide range of symptoms, from mild form to the severely affected classical male phenotype with early organ failure and associated morbidity and mortality.

Methods: Patients diagnosed with FD at Dr. Sami Ulus Maternity and Child Health Training and Research Hospital were enrolled. Phenotypic and genotypic presentations of 10 cases from three unrelated families have been evaluated. Diagnoses of relatives of index patients were reached by family screening. Clinical, laboratory and molecular genetic analysis of patients were collected.

Results: A total of 10 patients including 7 males, (mean age 31.8, range: 14-59 years) and 3 females, (mean age 44.6, range: 40-51 years) were evaluated. Various multisystem manifestations were observed, including cardiac, neurological, cerebrovascular and ophtalmological involvement. Eight out of ten patients had hypohydrosis, 4/10 had angiokeratomas and hearing loss. All male and female patients had abdominal pain and 9/10 had neuropathic pain. Among 7 male patients, 6 had renal complications and 2 of them reached end stage renal disease (ESRD) requiring renal replacement therapy. Concentric left ventricular hypertrophy, was the most common echocardiographic finding along with mitral regurgitation.


Conclusion:
ERT may slow down the progression of disease if inititated early. To ensure early diagnosis, it is important to recognize the symptoms of FD. Family screening may help patients to be identified at the presymptomatic phase of the disease. That’s why the awareness of pediatricians should be increased about Fabry Disease.

Keywords: Fabry Disease, multisystemic involvement, Alpha-galactosidase A

References

  1. 1. Lenders M, Brand E. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. J Am Soc Nephrol 2018;29:2265-2278.
  2. 2. Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease.Review. BiochimBiophysActa Gen Subj. 2020;1864:129437.
  3. 3. Effraimidis G, Feldt-Rasmussen U, Rasmussen ÅK, Lavoie P, Abaoui M, Boutin M, et al. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. J Med Genet 2020 Sep 22:jmedgenet-2020-107162.
  4. 4. Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neurosci Ther 2016; 22:568-576.
  5. 5. Simonetta I, Tuttolomondo A, Daidone M, Miceli S, Pinto A. Treatment of Anderson-Fabry Disease. Curr Pharm Des. 2020 Mar 17.
  6. 6. van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.
  7. 7. Koca S, Tümer L, Okur İ, Erten Y, Bakkaloğlu S, Biberoğlu G, et al. High Incidence of Co-Existing Factors Significantly Modifying the Phenotype in Patients With Fabry Disease. Gene 2019; 1;687:280-288.
  8. 8. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007;93:528–535.
  9. 9. Chan B, Adam DN. A Review of Fabry Disease. Skin Therapy Lett 2018;23:4-6.
  10. 10. Mehta A. Gınsberg L. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005;94:24–27.
  11. 11. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, et al; FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS –Fabry Outcome Survey. J Med Genet 2009;46:548-552.

How to cite

1.
Kasapkara ÇS, Olgac A, Yıldız İ, Kasapkara ÇS, Kılıç M. Retrospective Evaluation of Clinical and Molecular Characteristics of Patients with Fabry Disease Being Followed-Up in Our Clinic. Turk J Pediatr Dis [Internet]. 2021 Mar. 30 [cited 2025 May 24];15(2):117-22. Available from: https://turkjpediatrdis.org/article/view/803